GENMAB A/S reports $4.2B in DARZALEX sales
- DARZALEX net sales: $4.239B in Q3 2026
- U.S. net sales: $2.528B
- Rest of world net sales: $1.711B
GMAB
GENMAB A/S SEC filings
Every EDGAR filing for GENMAB A/S (GMAB), newest first, with AI summaries and stories.
- Ticker
- GMAB
- CIK
- 1434265
- Latest filing
- 6d
Filings
6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE GENMAB A/S grants 5,300 RSUs to board members
- 5,300 restricted stock units granted to board members
- Each RSU valued at DKK 2,487.00
- Vesting occurs after 3 years from grant date
6-KGENMAB A/SGNMSFLIVE GENMAB A/S reports positive trial results for epcoritamab
- Phase 3 trial showed 51% reduction in disease progression or death risk
- Epcoritamab combined with R-CHOP improved progression-free survival
- Trial involved patients with DLBCL and IPI scores of 2 to 5
SCHEDULE 13GGENMAB A/SGNMSFLIVE Genmab A/S: Darwin Global Management reports 5.9% stake
- Darwin Global Management, Ltd. holds 3,668,310 shares
- Dr. Abhishek Trehan holds 3,668,310 shares
- Darwin Global Master Fund, Ltd. holds 3,569,746 shares
Darwin Global Management, Ltd.
6-KGENMAB A/SGNMSFLIVE GENMAB A/S reports major shareholder update
- Darwin Global Management controls 5.11% of voting rights as of 9/28/2026
- Darwin holds shares and ADRs through investment funds
- Genmab is an international biotech company with 8 approved medicines
6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE SCHEDULE 13G/AGENMAB A/SGNMSFLIVE Ownership stake disclosure by ORBIS INVESTMENT MANAGEMENT LTD (amended)
ORBIS INVESTMENT MANAGEMENT LTD, filed by
6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE SCHEDULE 13G/AGENMAB A/SGNMSFLIVE Ownership stake disclosure by ORBIS INVESTMENT MANAGEMENT LTD (amended)
ORBIS INVESTMENT MANAGEMENT LTD, filed by
6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE SCHEDULE 13G/AGENMAB A/SGNMSFLIVE Ownership stake disclosure by ORBIS INVESTMENT MANAGEMENT LTD (amended)
ORBIS INVESTMENT MANAGEMENT LTD, filed by
S-8GENMAB A/SGNMSFLIVE 20-FGENMAB A/SGNMSFLIVE 6-KGENMAB A/SGNMSFLIVE